Valuation: Zai Lab Limited

Market Cap 2.94B 2.52B 2.36B 2.15B 4.07B 280B 4.11B 27.83B 10.83B 141B 11.03B 10.79B 468B P/E 2026 *
-11.6x
P/E 2027 * -12.2x
Enterprise Value 2.48B 2.13B 1.99B 1.82B 3.43B 236B 3.47B 23.49B 9.15B 119B 9.31B 9.11B 395B EV / Sales 2026 *
5.87x
EV / Sales 2027 * 4.5x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 week+1.82%
Current month+41.77%
1 month+32.54%
3 months+44.52%
6 months+36.59%
Current year+51.35%
1 week 20.6
Extreme 20.6
23
1 month 15.5
Extreme 15.5
23
3 years 12.6
Extreme 12.6
38.2
5 years 12.6
Extreme 12.6
127
Manager TitleAgeSince
Chief Executive Officer 61 31/03/2014
Director of Finance/CFO 58 06/07/2023
President 62 30/11/2022
Director TitleAgeSince
Chairman 61 31/03/2014
Director/Board Member 83 31/12/2016
Director/Board Member 75 31/12/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.45%+1.82%-23.29%+1.82% 2.94B
-1.13%-1.91%+40.35%-0.74% 83.24B
-0.69%+3.58%-19.85%-35.64% 59.49B
-4.86%-13.46%+510.23%+32.57% 63.41B
+0.76%+3.53%+0.08%+36.18% 52.94B
-1.70%+1.10%+10.24%+167.95% 49.86B
-0.16%-0.97%+60.48%-17.22% 32.62B
-0.60%-0.45%+52.26%+97.28% 26.29B
+9.69%+11.76%+14.67%+215.97% 22.23B
-0.89%-0.60%+59.81%+121.01% 17.22B
Average -0.02%+20.50%+70.50%+61.92% 45.26B
Weighted average by Cap. -0.85%+27.36%+96.73%+46.46%

Financials

2026 *2027 *
Net sales 423M 362M 339M 310M 585M 40.29B 591M 4B 1.56B 20.33B 1.59B 1.55B 67.32B 569M 487M 457M 417M 787M 54.23B 795M 5.39B 2.1B 27.36B 2.14B 2.09B 90.61B
Net income -245M -210M -197M -180M -339M -23.36B -343M -2.32B -904M -11.79B -920M -900M -39.03B -187M -160M -150M -137M -259M -17.82B -261M -1.77B -689M -8.99B -702M -687M -29.77B
Net Debt -458M -392M -367M -336M -633M -43.63B -640M -4.33B -1.69B -22.01B -1.72B -1.68B -72.9B -381M -326M -306M -279M -527M -36.31B -532M -3.61B -1.4B -18.32B -1.43B -1.4B -60.66B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
26/08/26 21.80 -2.68%
25/08/26 €22.40 +8.74%
24/08/26 €20.60 -7.21%
21/08/26 €22.20 0.00%
20/08/26 €22.20 -2.63%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
26.17USD
Average target price
32.39USD
Spread / Average Target
+23.77%

Quarterly revenue - Rate of surprise